PL1855682T3 - Postacie dawkowania aminopteryny do zastosowania w chorobach zapalnych - Google Patents

Postacie dawkowania aminopteryny do zastosowania w chorobach zapalnych

Info

Publication number
PL1855682T3
PL1855682T3 PL06748317T PL06748317T PL1855682T3 PL 1855682 T3 PL1855682 T3 PL 1855682T3 PL 06748317 T PL06748317 T PL 06748317T PL 06748317 T PL06748317 T PL 06748317T PL 1855682 T3 PL1855682 T3 PL 1855682T3
Authority
PL
Poland
Prior art keywords
aminopterin
dosage forms
inflammatory disorders
disorders
inflammatory
Prior art date
Application number
PL06748317T
Other languages
English (en)
Inventor
John A. Zebala
Original Assignee
Aminopterin Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aminopterin Llc filed Critical Aminopterin Llc
Publication of PL1855682T3 publication Critical patent/PL1855682T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL06748317T 2005-03-11 2006-03-08 Postacie dawkowania aminopteryny do zastosowania w chorobach zapalnych PL1855682T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/078,271 US7312217B2 (en) 2005-03-11 2005-03-11 Aminopterin dosage forms and methods for inflammatory disorders
PCT/US2006/008233 WO2006098979A2 (en) 2005-03-11 2006-03-08 Aminopterin dosage forms and methods for inflammatory disorders
EP06748317.2A EP1855682B1 (en) 2005-03-11 2006-03-08 Aminopterin dosage forms for inflammatory disorders

Publications (1)

Publication Number Publication Date
PL1855682T3 true PL1855682T3 (pl) 2018-04-30

Family

ID=36971856

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06748317T PL1855682T3 (pl) 2005-03-11 2006-03-08 Postacie dawkowania aminopteryny do zastosowania w chorobach zapalnych

Country Status (6)

Country Link
US (5) US7312217B2 (pl)
EP (1) EP1855682B1 (pl)
JP (2) JP5791864B2 (pl)
ES (1) ES2658070T3 (pl)
PL (1) PL1855682T3 (pl)
WO (1) WO2006098979A2 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1789391B1 (en) 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
US7312217B2 (en) * 2005-03-11 2007-12-25 Syntrix Biosystems, Inc. Aminopterin dosage forms and methods for inflammatory disorders
EP2139523B1 (en) 2007-03-14 2014-10-22 Endocyte, Inc. Conjugates of folate and tubulysin for targeted drug delivery
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
BRPI0812970A2 (pt) 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos
AU2010206631B2 (en) * 2009-01-24 2016-03-31 Aminopterin Llc. Pharmaceutical composition comprising racemic aminopterin
WO2012047525A2 (en) * 2010-09-27 2012-04-12 Endocyte, Inc. Folate conjugates for treating inflammation of the eye
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
MX2015004757A (es) 2012-10-16 2015-07-17 Endocyte Inc Conjugados de suministro de farmacos que contienen aminoacidos no naturales y metodo para usarlos.
EP3337491A4 (en) * 2015-08-19 2019-04-10 Children's Research Institute, Children's National Medical Center COMPOSITIONS AND METHODS FOR TREATING TRANSPLANT HOST REACTION
CN106046005A (zh) * 2016-08-19 2016-10-26 常州市新鸿医药化工技术有限公司 一种叶酸合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2575168A (en) 1948-07-22 1951-11-13 American Cyanamid Co Rodenticide comprising 4-aminopteroylglutamic acid
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4079056A (en) 1975-03-31 1978-03-14 The United States Of America As Represented By The Department Of Health, Education And Welfare Method of making pteridine compounds
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
CH630380A5 (de) 1977-08-12 1982-06-15 Lonza Ag Verfahren zur herstellung von l-methotrexat.
GB8322007D0 (en) 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
FR2590255B1 (fr) 1985-11-19 1987-12-24 Rhone Poulenc Sante Procede de preparation de derives de la pteridine
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
US20020037899A1 (en) * 2000-08-10 2002-03-28 Baggott Joseph E. Compositions containing an inhibitor of dihydrofolate reductase and a folate
US20040176381A1 (en) * 2003-03-06 2004-09-09 Walsh Michael J. Methotrexate compliance packaging
US7612071B2 (en) * 2004-03-12 2009-11-03 Syntrix Biosystems, Inc. Compositions and methods employing aminopterin
DE102004016355A1 (de) * 2004-04-02 2005-11-03 Rösner Research GmbH & Co.KG Herstellung und Verwendung des Konjugats Methotrexat-Albumin als Mittel zur Immunosuppression bei GVHD
US7312217B2 (en) 2005-03-11 2007-12-25 Syntrix Biosystems, Inc. Aminopterin dosage forms and methods for inflammatory disorders
AU2010206631B2 (en) * 2009-01-24 2016-03-31 Aminopterin Llc. Pharmaceutical composition comprising racemic aminopterin

Also Published As

Publication number Publication date
ES2658070T3 (es) 2018-03-08
US20080096893A1 (en) 2008-04-24
US20080108621A1 (en) 2008-05-08
EP1855682A4 (en) 2008-05-07
EP1855682B1 (en) 2017-11-01
JP2013209384A (ja) 2013-10-10
WO2006098979A2 (en) 2006-09-21
US7312217B2 (en) 2007-12-25
JP2008533022A (ja) 2008-08-21
US20120128703A1 (en) 2012-05-24
US20170128452A1 (en) 2017-05-11
US20060205729A1 (en) 2006-09-14
JP5791864B2 (ja) 2015-10-07
US8129383B2 (en) 2012-03-06
US9867828B2 (en) 2018-01-16
WO2006098979A3 (en) 2006-11-30
EP1855682A2 (en) 2007-11-21

Similar Documents

Publication Publication Date Title
PL1855682T3 (pl) Postacie dawkowania aminopteryny do zastosowania w chorobach zapalnych
IL180187A (en) Composition for treating inflammatory disorders
IL194739A0 (en) Dihydrothienopyrimidine for treating inflammatory disorders
IL192692A0 (en) Compounds for the treatment of inflammatory disorders
EP2010187A4 (en) CONNECTIONS FOR DISEASES AND FUNCTIONAL DISORDERS
IL184456A0 (en) Dosage form for treating gastrointestinal disorders
EP1833467A4 (en) PHARMACEUTICAL COMPOSITIONS FOR SLEEP DISORDERS
IL192691A0 (en) Hydantoin compounds for the treatment of inflammatory disorders
GB0508306D0 (en) Nicotine dosage forms
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
IL197001A0 (en) Combination treatment for metabolic disorders
EP1840395A4 (en) rolling device
EP1901733A4 (en) USE OF HUPERZINE FOR DISEASES
HK1112418A1 (en) Herbal composition for inflammatory disorders
GB0513984D0 (en) Dosage form
IL183447A0 (en) Substituted pteridines for treating inflammatory diseases
EP1812730A4 (en) ANTI-GAME NUT
ZA200806455B (en) Use of 2-imidazoles for the treatment of CNS disorders
EP1806145A4 (en) MEDICINE FOR THE TREATMENT OF INFLAMMATORY DISEASES
GB0601179D0 (en) Therapies for psychotic disorders
GB2426029B (en) Adjustable staircase
GB0427455D0 (en) Dosage forms
HK1134032A1 (en) New combination for use in the treatment of inflammatory disorders
EP1720569A4 (en) TARGET FOR B-CELL DISORDERS
IL192877A0 (en) Use of 2-imidazoles for the treatment of cns disorders